European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

BioNTech Diagnostics GmbH, Mainz, Germany

Watch
BioNTech Diagnostics GmbH

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier is a comprehensive company details as a PDF and publications in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Complete Dossier
Entire company details along with publications bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans
Risk report
BioNTech Diagnostics GmbH
Risk Level Evaluation Source
Sanctioned (?)

Name

BioNTech Diagnostics GmbH
Theracode GmbH

Identification

Ut
District Court of Mainz HRB 41988
EUID
DET2304V.HRB41988

Address

An der Goldgrube 12, 55131 Mainz, Germany

Corporate purpose

The research, development, manufacture and distribution of therapy-relevant diagnostics and reagents intended for research purposes

Financial performance

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information · Proxy policies Premium
Premium
2Managing Director
1Authorized signatory (ppa)
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
CSV export

Quarterly Exports in CSV

Now available in CSV format and optimized for applications in AI and Analytics:
North Data's quarterly exports have become the industry standard for company information.

Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
One known shareholder
Portfolio and Investments
One known active shareholding
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Revenue
Equity
Trademarks
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

8 Jul 2026
No longer Authorized signatory (ppa): Lynn Miriam Voigt
Year 2026 in Dpmam
4 trademark filings: CLAUDENTIFY …
29 May 2026 via BioNTech SE also 29/04/2026, 05/06/2025, 02/06/2025, 06/06/2024, 06/06/2024, 10/05/2023, 10/05/2023, 22/04/2022, 20/04/2022, 03/05/2021, 27/04/2021, 09/06/2020, 29/01/2020, 02/01/2020
Shareholder: BioNTech SE
23 May 2026
Wordmark: “TCR-Typer“
23 May 2026
Wordmark: “BCR-Typer“
5 May 2026
Managing Director: Dennis Oliver Ball · No longer Managing Director: Ugur Sahin · No longer Authorized signatory (ppa): Dennis Oliver Ball
12 Mar 2026
Wordmark: “BladderTyper“
4 Nov 2025
Wordmark: “BCR-Typer“
4 Nov 2025
Wordmark: “TCR-Typer“
4 Feb 2025
Authorized signatory (ppa): Dennis Oliver Ball
16 Dec 2024
Managing Director: Sierk Pötting, Ugur Sahin · Authorized signatory (ppa): Dirk Schreiber, Lynn Miriam Voigt
21 Apr 2024
Wordmark: “LungTYPER“
19 Dec 2023
Authorized signatory (ppa): Dirk Schreiber, Lynn Miriam Voigt · No longer Authorized signatory (ppa) (3)
1 Mar 2023 in Fk
Public funding (€38,713): curATime: Atherothrombosis-associated autoantibody signatures as disease predictors and biomarkers for diagnosis and therapy (curABodies) - C
27 Apr 2022
Patent: Methods and Kits for Molecular Subtyping of Bladder Cancer
1 Feb 2022
Wordmark: “BCR-Typer“
1 Feb 2022
Wordmark: “CLAUDENTIFY“
1 Feb 2022
Wordmark: “TCR-Typer“
3 Dec 2021
Wordmark: “RNXtract“
3 Dec 2021
Wordmark: “RNXtract“
7 Jan 2021 via JPT Peptide Technologies GmbH also 06/01/2021
No longer Profit Transfer: JPT Peptide Technologies GmbH
27 May 2020 via BioNTech SE
Shareholding: BioNTech SE
22 Oct 2019
Wordmark: “CLAUDENTIFY“
26 Sept 2019
Patent: Predictive and Prognostic Methods for Breast Cancer
26 Jul 2019
Wordmark: “MAMMATYPER“
26 Jul 2019
Wordmark: “MammaTyper“
12 Jun 2019
Patent: Method and kit for determining the presence of an immune response in a subject
12 Jun 2019
Patent: Methods and Kits for Diagnosing Lung Cancer
22 May 2019
Authorized signatory (ppa) (3)
13 May 2019
Original document: “Liste der Gesellschafter“
9 May 2019
Original document: “Liste der Gesellschafter“
21 Feb 2019 via BioNTech AG also 14/02/2019, 05/06/2018, 28/02/2018, 07/02/2018, 06/02/2018, 27/01/2017, 26/01/2017, 08/11/2016, 28/10/2016, 01/07/2016, 13/04/2016, 15/06/2015, 05/03/2015, 09/01/2014, 20/03/2013, 27/09/2011, 23/08/2010
Shareholder: BioNTech AG
1 Feb 2019
Wordmark: “Theracode“
8 Aug 2018
Patent: Methods and kits for molecular subtyping of tumors
25 Jun 2018
Wordmark: “Theracode“
13 Jul 2017
Wordmark: “Theracode“
28 Jun 2017
Managing Director: Sierk Poetting, Ugur Sahin
15 Apr 2016
Share­holder agreement · Corporate Purpose
11 Apr 2016
Original document: “Gesellschaftsvertrag / Satzung / Statut“
30 Mar 2016
Patent: Algorithm for Prediction of Benefit From Addition of Taxane to Standard Chemotherapy in Patients with Breast Cancer
10 Feb 2016
Wordmark: “MAMMATYPER“
Year 2015 in Dpmap
12 patent filings: Verfahren und Kits zur Diagnose von Lungenkrebs …
Year 2015 in Dpmam
4 wordmarks: BCR-Typer, RNXtract, TCR-Typer, Theracode …
12 Sept 2014
Managing Director: Sierk Poetting · No longer Managing Director (1)
16 May 2014
Patent: Methods and Kits for the Diagnosis of Cancer
Year 2014 in Dpmam
3 wordmarks: MammaTyper, RNXtract, Theracode …
13 Mar 2014
Address · Share­holder agreement · Name: BioNTech Diagnostics GmbH
5 Mar 2014
Address · Name: BioNTech Diagnostics GmbH
20 Feb 2014
Original document: “Gesellschaftsvertrag / Satzung / Statut“
31 Jan 2014
Wordmark: “RNXtract“
10 Jan 2014 as Theracode GmbH
Annual report for the year ending 31/12/2012 · Balance sheet for 31/12/2012 · Persons · Shareholdings: JPT Peptide Technologies GmbH, Theracode JPT Inc
8 Aug 2013
Wordmark: “MammaTyper“
14 Feb 2013 as Theracode GmbH
Annual report for the year ending 31/12/2011 · Balance sheet for 31/12/2011 · Shareholdings: JPT Peptide Technologies GmbH / Berlin, Theracode JPT Inc. / Orlando, Florida USA
1 Jan 2013 in Fk
Public funding (€261,188): CI3: NAUTICAL - Use of Autoantibody Signatures as a Test Procedure in Early Cancer Detection, Project Part Theracode
28 Nov 2012 as Theracode GmbH
Managing Director (1)
1 Oct 2012 in Fk
Public funding (€340,251): CI3: Development of a microfluidics-based system for the enrichment and single-cell analysis of circulating tumor cells, Theracode project part
1 Apr 2012 in Fk
Public funding (€176,804): CI3: Biomarker for L-BLP25/Stimuvax, Subproject Theracode
26 Sept 2011 as Theracode GmbH
Annual report for the year ending 31/12/2010 · Balance sheet for 31/12/2010 · Shareholdings: JPT Peptide Technologies GmbH, Theracode JPT Inc
1 Aug 2011 in Fk
Public funding (€159,966): Oncoprofile Kit - Sequencing and Bioinformatics for Biomarker Identification
28 Mar 2011 as Theracode GmbH
Managing Director: Ugur Sahin
16 Mar 2011
Managing Director: Ugur Sahin
26 Oct 2010 as Theracode GmbH
Managing Director (1)
12 Oct 2010
Managing Director (1)
24 Aug 2010 as Theracode GmbH
Annual report for the year ending 31/12/2009 · Balance sheet for 31/12/2009 · Shareholder: JPT Peptide Technologies GmbH, Theracode JPT Inc
9 Aug 2010
Change of name or address: Wordmark: “Theracode“
4 Aug 2010 as Theracode GmbH
Address
16 Jul 2010
Address
26 May 2010
Wordmark: “Theracode“
2 Feb 2010
Change of name or address: Wordmark: “Theracode“
5 Jan 2010 as Theracode GmbH
Profit Transfer: BioNTech AG · Control: BioNTech AG
28 Dec 2009
Profit Transfer: BioNTech AG · Control: BioNTech AG
9 Dec 2009
Original document: “Unternehmensvertrag / Umwandlungsvertrag / sonstiger Vertrag“
19 Aug 2009 as Theracode GmbH
Profit Transfer: BioNTech AG · Control: BioNTech AG
4 May 2009 as Theracode GmbH
Reg­is­tra­tion · Managing Director (1) · Address · Capital: €25,000 · Share­holder agreement · Proxy policy · Corporate Purpose
23 Apr 2009 as Theracode GmbH
Reg­is­tra­tion · Managing Director (1) · Address · Capital: €25,000 · Legal form: GmbH · Name: Theracode GmbH · Corporate Purpose
25 Mar 2009
Original document: “Liste der Gesellschafter“
25 Mar 2009
Original document: “Gesellschaftsvertrag / Satzung / Statut“
There are no publications matching your search.

Mentions

18 Jun 2020 in Hrdk also 15/06/2020, 07/05/2009
JPT Peptide Technologies GmbH: “Liste der Gesellschafter“
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.